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Background: The six-minute-walk-test (6MWT) has been increasingly used in cystic ﬁbrosis (CF) patients. However, few studies in children have
correlated 6MWT with current parameters used to evaluate CF severity. Moreover, no study transformed the values of distance walked from meters
into Z scores to avoid bias like age and gender, which are sources of 6MWT variability.
Methods: A cross-sectional descriptive study was performed to analyze the correlations (Spearman) among forced expiratory volume in one second
(FEV1), body mass index (BMI), chest radiography (CXR), chest tomography (CT), and 6MWT Z score (Z-6MWT). Clinically stable CF patients,
aged 6–21 years, were included.
Results: 34 patients, 14F/20M, mean age 12.1±4.0 years were studied. The mean Z-6MWT was −1.1±1.106. The following correlations versus Z-
6MWT were found: FEV1 (r=0.59, r
2=0.32, p=0.0002), BMI Z score (r=0.42, r2=0.17, p=0.013), CXR (r=0.34, r2=0.15, p=0.0472) and CT
(r=−0.45, r2=0.23, p=0.0073).
Conclusions: In conclusion there was a signiﬁcant, but poor, correlation between the six minute walk test Z score and the cystic ﬁbrosis severity
markers currently in use.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Chest imaging; function tests; minute walk test; ﬁbrosis1. Introduction
In cystic fibrosis (CF) disease progression is assessed
through spirometry, chest radiography and tomography and
clinical data [1–3]. In the last decade, the six-minute walk test
(6MWT) has been widely used to evaluate global exercise ca-
pacity in patients with cystic fibrosis [4–8] and it has been pro-
posed as a simple and reliable test for the periodic evaluation of
CF patients' exercise program [4,9]. It is a low cost test, easy toAbbreviations: CF, cystic fibrosis; CXR, chest radiography; CT, chest computed
FVC, forced vital capacity; FEV1, forced expiratory volume in one second; FEF25-75%
index.
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doi:10.1016/j.jcf.2011.11.009perform, reproducible and may serve as a predictor of mortality
and morbidity in patients with cardiopulmonary diseases
[4,10,11,12]. It is also useful for longitudinal assessment, to
monitor response to treatment and to guide therapy [11,13].
The 6MWT has been increasingly used in young children,
for whom performing cardiopulmonary exercise tests is espe-
cially problematic, requiring a high degree of cooperation,
good coordination and motivation [10,14]. It has to be taken
into account that there is a degree of practice bias with thetomography scan; PFT, pulmonary function tests; 6MWT, six minute walk test;
, forced expiratory flow between 25 and 75% of vital capacity; BMI, body mass
s Clínicas, University of São Paulo, Av. Dr Enéas Carvalho de Aguiar, 647, São
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come [10]. Up to now, few studies in children have correlated
6MWT with current parameters used to evaluate CF severity.
Moreover, no study transformed the values of distance walked
from meters into Z scores to avoid bias like age and gender,
which are sources of 6MWT variability.
In this study we transformed the values of distance walked
in the 6MWT from meters into Z scores and investigated the
correlations between six minute walk test Z score (Z-6MWT)
and other current parameters used to evaluate CF severity,
such as forced expiratory volume in one second (FEV1), body
mass index (BMI), chest radiography (CXR) and chest computed
tomography (CT).
2. Methods
This was a cross-sectional descriptive study. Between June
2006 and August 2008, we studied 34 CF patients (between 6
and 21 years old) recruited from the outpatient clinic of our
hospital. The diagnosis of cystic fibrosis was made according
to established criteria [15]. Only patients with stable disease
were included in this study. Exclusion criteria were pulmonary
exacerbation [16] in the month preceding the tests or a chest CT
done in the previous year to avoid another radiation exposure.
Spirometry, chest radiography and CT and the 6MWT were
all carried out on the same morning.
This study was approved by the Human Ethics Committee
of Hospital das Clínicas — Medical School of University of
São Paulo, Brazil (approval number 1074/05). Written in-
formed consent was obtained from all subjects or their parents.
2.1. Spirometry
Spirometry was performed by a single technician with expe-
rience in pediatric tests, using the standards recommended by
the American Thoracic Society (ATS) [17]. A Master Screen
spirometer (Multispiro Creative Biometcs) was used. The re-
sults were expressed as the percentage of predicted values for
forced vital capacity (FVC), FEV1 and forced expiratory flow
between 25 and 75% of vital capacity (FEF25-75%). The equa-
tions of Polgar and Promadhat were used as a reference for sub-
jects up to 17 years of age, and the equation of Knudson et al.
was used for patients aged between 18 and 21 years [18,19].
The severity of the ventilatory obstruction was classified
according to ATS/ERS (European Respiratory Society) [20].
2.2. Chest radiography and chest CT scan
The Brasfield score [21] was used to evaluate chest radiogra-
phy. Five categories were scored: air trapping, linear marks,
nodular cystic lesions, large lesions, and overall severity. Chest
roentgenograms showing more severe changes received a lower
score.
The CT scans were scored using the scoring system described
by Bhalla et al. [22]. In 25 patients chest CT during expiration
was also performed and it was possible to calculate a modified
Bhalla score [23]. Bhalla score was used instead of the modifiedBhalla score for the correlation analysis because it was applied in
all patients and a significant correlation between the modified
Bhalla score and the Bhalla score was found (r=0.97,
pb0.0001).
Scanning was performed with a GE LightSpeed Ultra CT
Scanner. Thin-section CT scans were obtained using a beam
current automatically adjusted by the machine (70–100 mA), an
exposure time of 0.5 s, a beam potential of 120 kV from lung
apex to lung base at 10 mm intervals using 1.25 mm thick single
slices, non volumetric, and a field of view of 15–40 cm. Mean
CTDI vol was 1.3 mGy. All scans were reconstructed with a
high spatial frequency algorithm (bone) and printed with window
settings appropriate for the imaging of pulmonary parenchyma
(window width—600 HU; window level—1.500 HU).
The radiographic and tomographic scores were calculated
independently in a blinded manner by three radiologists (two
pediatric radiologists and a chest radiologist). The final score
was the average of the three radiologists' scores.
2.3. Six-minute walk test
All 6MWTs were done using a lap 30 m in length, on a flat,
hard surface, according to the ATS guidelines [10]. Two tests
were performed on the same day with an interval of at least
30 min and after all clinical variables had returned to their
basal values. The patients were asked to walk as far as possible
for 6 min up and down the measured lap, but not to run. Stan-
dardized encouragement was given by the same person after
every 1 min (“You are doing well!”, “Keep up the good
work!”). The distance was measured in meters and the test
with the greatest distance was selected. The values were trans-
formed into Z scores based on Geiger et al. data [24], using the
following formula: value found−normal value/standard
deviation.
2.4. Statistical analysis
Data were expressed as number of cases, mean and standard
deviation or median. Mean±SD was used for parametric data
(age, BMI, 6MWT, spirometry) and median was used for non-
parametric data (Bhalla and Brasfield scores). Linear regression
(Spearman's correlation coefficient) was used for analysis of cor-
relations between the tests, calculated by the GraphPadPrism 5
program. The significance level considered was pb0.05.
It was calculated that a minimum sample size of 30 patients
was needed in order to estimate correlations with a level of sig-
nificance of α=0.05 and a statistical power (1-ß) of 95% (Med-
Calc software version 10.0.0).
The BMI of patients was calculated and transformed into Z
scores (Z-BMI) using the program Nutrition Epi Info™, ver-
sion 3.3.2 on the CDC website.
3. Results
Thirty-four patients were evaluated, 14 females and 20 males,
mean age of 12.1±4 years. The descriptive characteristics of pa-
tients are shown in Table 1. The mean distance walked was 596±
Table 1
Characteristics of the CF patients (n=34).
Mean±sd Range
Age (years) male/female: 20/14 12.1±4.0 6.0–20.9
Z-BMI −0.6±1.2 −2.9–2.1
BMI (Kg/m2) 17.0±2.4 13.7–22
Z-6MWT −1.1±1.106 −4.07–0.6
6MWT (m) 595.9±68.8 431.0–743.0
FVC (% predicted) 70.4±25.9 20.4–126.0
FEV1 (% predicted) 59.2±26.0 13.3–134.0
FEF25-75% (% predicted) 47.4±35.8 4.8–172.4
Bhalla score (median) 10.8 2.7–19.0
Brasfield score (median) 15.7 6.0–23.7
Z-BMI, body mass index Z score; Kg, kilogram; m, meters; Z-6MWT, six-
minute walk test Z score; FVC, forced vital capacity; FEV1, forced expiratory
volume in 1 s; FEF25-75%, forced expiratory flow between 25 and 75% of
vital capacity.
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tional status the average BMI was 17±2.4 Kg/m2. Spirometry
showed 11 children with mild obstructive lung disease
(FEV1≥70%) or normal FEV1 (FEV1≥80%), seven moderate
(FEV1 between 60 and 69%), five moderately severe (FEV1
between 50 and 59%), six severe (FEV1 between 35 and 49%)
and five very severe (FEV1b35%).
For all patients the correlations between Z-6MWT and FEV1,
Z-BMI, Brasfield score and Bhalla score were calculated. A sig-
nificant correlation between all parameters was observed
(Figs. 1A, B, C and D).5 10 15 20 25
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Fig. 1. A) Correlation between Brasfield score and six minute walk test Z score (Z-6M
C) Correlation between Bhalla score and Z-6MWT; D) Correlation between forced4. Discussion
In the present study, the Z-6MWT correlated significantly
with current parameters used to evaluate CF severity such as
FEV1, Z-BMI, chest radiography and tomography. Despite the
statistically significant correlation that was found the correlation
coefficients and plots did not show a very tight correlation and
this may reflect that the 6MWT is affected by other extra pulmo-
nary domains [10].
Although reference values for 6MWT in Brazilian children
have recently been published [25] we decided to use Geiger
et al. [24] reference values because our sample consisted of pa-
tients up to 21 years old and the Brazilian data only included
patients younger than 12 years of age. Nevertheless, the Brazil-
ian data on reference values for the 6MWT strongly correlated
with the data of Geiger et al. (r=0.87).
Previous studies in CF patients did not show significant corre-
lations between 6MWT and pulmonary function tests [4,26,27],
BMI [8,26] and chest radiography [8]. Different from these stud-
ies we decided to transform the values of distance walked from
meters into Z score based on reference values from healthy
population to avoid bias like age and gender, which are sources
of 6MWT variability [10,24,28,29]. The use of the Z score to rep-
resent the distance walked was able to render uniform the data of
the population studied, which had a wide age range (6 to 21 years
old).
Only two studies found significant correlations between
6MWT and FEV1 (r=0.53 to r=0.75), but one evaluated CF-4 -2 0 2
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WT); B) Correlation between body mass index Z score (Z-BMI) and Z-6MWT;
expiratory volume in 1 s (FEV1) and Z-6MWT.
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other obstructive lung disease were included [30].
The poor correlation we found between the Brasfield and
Bhalla scores and the Z-6MWT may be due to the fact that
the 6MWT reflects the overall status of both lungs while
CXR and CT can help identify abnormalities that affect only
a small portion of the lung. The correlation between 6MWT
and chest CT has not been described before.
One limitation of our study is that it is a cross-sectional
study and this precludes a longitudinal evaluation. It was not
possible to assess whether or not the parameters (CXR, CT,
FEV1, 6MWT) would change in a similar way.
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